This underscores the importance of investigating novel therapeutic targets such as targeting TLR4 signaling or its downstream cAMP/cGMP pathway to restore prostaglandin-dependent inhibitory signaling and mitigate platelet-driven hypercoagulability in cats with high thrombotic risk. Here, TLR4 is linked to thrombophilia.